AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cidara Therapeutics Inc. (CDTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

21.84

-1.97 (-8.27%)

At close: Feb 20, 2025, 3:59 PM

22.38

2.47%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	21.42
Market Cap	239.04M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-23.9
PE Ratio (ttm)	-0.91
Forward PE	n/a
Analyst	Buy

Ask	23.34
Volume	74,019
Avg. Volume (20D)	105,401
Open	23.40
Previous Close	23.81
Day's Range	20.63 - 23.00
52-Week Range	10.00 - 28.42
Beta	undefined

About CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 15, 2015

Employees 69

Stock Exchange NASDAQ

Ticker Symbol CDTX

Website https://www.cidara.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 51.10% from the latest price.

Buy 83.33%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Cidara Therapeutics Inc. is scheduled to release its earnings on Apr 21, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+15.41%

Cidara Therapeutics shares are trading higher. The... Unlock content with Pro Subscription

10 months ago

+5.78%

Cidara Therapeutics shares are trading higher after the company announced the divestiture of rezafungin to Mundipharma, reacquired global development and commercial rights to CD388 and announced $240 million in private placement financing.

News

1 week ago · seekingalpha.com

Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention

Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388...

2 months ago · zacks.com

Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?

Cidara Therapeutics, Inc. (CDTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CDTX's 50-day simple moving average crossed ...

3 months ago · seekingalpha.com

Cidara: Potential To Change Flu Prophylaxis Landscape With CD388

Results from phase 2b NAVIGATE study, using CD388 as a prophylaxis for Flu, expected to be released Q3 of 2025. CD388 offers broad influenza A and B coverage regardless of strain type and even effecti...